Trial Profile
Evaluation in 3 moNths Duration of nEointimAl coVerAge After zOtaRolimus-Eluting Stent Implantation by Optical Coherence Tomography (ENDEAVOR OCT).
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 12 Dec 2009
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Registrational
- Acronyms ENDEAVOR OCT
- 28 Jan 2009 New trial record